American journal of ophthalmology case reports · 2026
Optic nerve infiltration in chronic lymphocytic leukemia treated with acalabrutinib monotherapy: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shakarchi Fatma F, Chacko Joseph A, Chacko Joseph G, Govindarajan Rangaswamy, Zent Clive S, Uwaydat Sami H
Аннотация
PURPOSE: We demonstrate the potential role of acalabrutinib, a second-generation selective Bruton tyrosine kinase (BTK) inhibitor, as monotherapy in treating optic nerve infiltration by chronic lymphocytic leukemia (CLL).
OBSERVATIONS: A 68-year-old male, initially diagnosed with CLL 13 years earlier, presented with a decrease in vision and intermittent floaters for 5 days. On fundus examination, there was optic disc swelling in both eyes (OU) concerning for CLL infiltration and vitreous haze in the left eye (OS). The MRI of the brain and orbit was normal, and his infectious and uveitis workups were unremarkable. He was prescribed acalabrutinib 100 mg twice daily by mouth. Five days later, the optic disc edema OU and vitreous haze OS improved and completely subsided two months later.
CONCLUSIONS AND IMPORTANCE: Early initiation of acalabrutinib may be sufficient therapy for CLL optic nerve infiltration.
OBSERVATIONS: A 68-year-old male, initially diagnosed with CLL 13 years earlier, presented with a decrease in vision and intermittent floaters for 5 days. On fundus examination, there was optic disc swelling in both eyes (OU) concerning for CLL infiltration and vitreous haze in the left eye (OS). The MRI of the brain and orbit was normal, and his infectious and uveitis workups were unremarkable. He was prescribed acalabrutinib 100 mg twice daily by mouth. Five days later, the optic disc edema OU and vitreous haze OS improved and completely subsided two months later.
CONCLUSIONS AND IMPORTANCE: Early initiation of acalabrutinib may be sufficient therapy for CLL optic nerve infiltration.